Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
154
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment.

Gut microbes·2026
Same author

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps.

Cancer·2026
Same author

Optimising rare tumour risk syndromes care: clinical insights and the PREVENTABLE socioeconomic framework.

European journal of human genetics : EJHG·2026
Same author

Latitude and feeding behavior affect persistent organic pollutant concentrations in Andean condors.

Journal of hazardous materials·2026
Same author

Pesticide fate and transport in the atmosphere and implications for risk assessment.

Journal of hazardous materials·2026
Same author

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

相关实验视频

Updated: Jun 16, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.1K

尼拉帕里布加芳酶抑制剂用于激素受体阳性/HER2-阴性先进乳腺癌,具有生殖线BRCA突变.

Laura Lema1, José Manuel Pérez-García2,3, Salvador Blanch4

  • 1Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.

Cancers
|June 13, 2025
PubMed
概括
此摘要是机器生成的。

尼拉帕里布加上芳酶抑制剂在具有BRCA突变的晚期乳腺癌患者中显示出有前途的结果. 这种组合疗法满足了其主要终点,显示出显著的临床益处和可管理的安全性.

关键词:
这是一种BRCA突变.HR+/HER2− 乳腺癌的治疗方法晚期乳腺癌是什么?芳香酶抑制剂的使用尼拉帕里布里布里布.

更多相关视频

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.2K

相关实验视频

Last Updated: Jun 16, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.2K

科学领域:

  • 在瘤学瘤学.
  • 遗传学 是一个遗传学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 尼拉帕里布是一种多 (腺二酸盐-糖) 聚合酶抑制剂,在治疗具有生殖系BRCA1/2突变的晚期乳腺癌方面具有潜力.
  • 激素受体阳性 (HR+) /HER2阴性晚期乳腺癌通常会对标准疗法产生耐药性,需要新的治疗策略.

研究的目的:

  • 评估在HR+/HER2-晚期乳腺癌患者中将尼拉帕里布与芳香酶抑制剂 (AI) 结合使用的疗效和安全性.
  • 具体评估生殖系BRCA1/2突变患者 (A组) 的结局,并探索野生型BRCA和同源重组缺陷 (B组) 患者的结局.

主要方法:

  • LUZERN试验是一个多中心的,开放的,II期临床试验 (NCT04240106).
  • 患者接受了尼拉巴里布 (300毫克或200毫克) 与AI结合,接受了≤1线化学疗法和1-2线先前的内分泌疗法治疗晚期疾病.
  • 主要终点是A队 (生殖系BRCA1/2突变携带者) 的临床益处率 (CBR).

主要成果:

  • 14名患者被纳入A队列;B队列没有被纳入. 随访时间的中位数为16.7个月.
  • 队列A中的CBR为46.2% (95%CI:19.2-74.9),符合主要终点.
  • 无进展生存时间的中位数为5.5个月 (95% CI: 1.9-8.5),总生存时间的中位数为18.1个月 (95% CI: 9.7-NE). 安全性概况与已知的药物毒性一致.

结论:

  • 与AI结合的Niraparib显示,在患有AI耐药HR+/HER2-晚期乳腺癌和生殖系BRCA1/2突变的患者中,可以鼓励抗瘤活性.
  • 组合疗法显示出可管理的安全性概况,支持其作为这种患者群体的治疗选择的潜力.